nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—polycystic ovary syndrome	0.714	1	CbGaD
Loperamide—POMC—urine—polycystic ovary syndrome	0.0123	0.186	CbGeAlD
Loperamide—Distention—Metformin—polycystic ovary syndrome	0.00873	0.275	CcSEcCtD
Loperamide—Abdominal bloating—Metformin—polycystic ovary syndrome	0.00432	0.136	CcSEcCtD
Loperamide—POMC—adrenal cortex—polycystic ovary syndrome	0.00327	0.0492	CbGeAlD
Loperamide—POMC—pituitary gland—polycystic ovary syndrome	0.00264	0.0397	CbGeAlD
Loperamide—POMC—adipose tissue—polycystic ovary syndrome	0.00263	0.0396	CbGeAlD
Loperamide—POMC—adrenal gland—polycystic ovary syndrome	0.00236	0.0355	CbGeAlD
Loperamide—CACNA1A—adrenal gland—polycystic ovary syndrome	0.00225	0.0339	CbGeAlD
Loperamide—POMC—female gonad—polycystic ovary syndrome	0.0022	0.0331	CbGeAlD
Loperamide—POMC—vagina—polycystic ovary syndrome	0.00219	0.0329	CbGeAlD
Loperamide—POMC—endocrine gland—polycystic ovary syndrome	0.00205	0.0308	CbGeAlD
Loperamide—CYP3A4—urine—polycystic ovary syndrome	0.00189	0.0285	CbGeAlD
Loperamide—CYP2D6—urine—polycystic ovary syndrome	0.00186	0.028	CbGeAlD
Loperamide—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00136	0.043	CcSEcCtD
Loperamide—Abdominal distension—Metformin—polycystic ovary syndrome	0.0013	0.041	CcSEcCtD
Loperamide—Drowsiness—Metformin—polycystic ovary syndrome	0.00115	0.0363	CcSEcCtD
Loperamide—CALM3—adrenal cortex—polycystic ovary syndrome	0.00114	0.0171	CbGeAlD
Loperamide—CALM2—embryo—polycystic ovary syndrome	0.00109	0.0164	CbGeAlD
Loperamide—CALM1—embryo—polycystic ovary syndrome	0.00108	0.0163	CbGeAlD
Loperamide—CALM3—endometrium—polycystic ovary syndrome	0.00101	0.0153	CbGeAlD
Loperamide—CALM3—uterus—polycystic ovary syndrome	0.000935	0.0141	CbGeAlD
Loperamide—Immune system disorder—Metformin—polycystic ovary syndrome	0.000933	0.0294	CcSEcCtD
Loperamide—CALM3—pituitary gland—polycystic ovary syndrome	0.000918	0.0138	CbGeAlD
Loperamide—CALM3—adipose tissue—polycystic ovary syndrome	0.000915	0.0138	CbGeAlD
Loperamide—CALM2—adrenal cortex—polycystic ovary syndrome	0.000893	0.0134	CbGeAlD
Loperamide—CALM1—adrenal cortex—polycystic ovary syndrome	0.000889	0.0134	CbGeAlD
Loperamide—Flatulence—Metformin—polycystic ovary syndrome	0.000886	0.028	CcSEcCtD
Loperamide—CALM3—adrenal gland—polycystic ovary syndrome	0.000821	0.0123	CbGeAlD
Loperamide—CALM2—endometrium—polycystic ovary syndrome	0.000797	0.012	CbGeAlD
Loperamide—CALM1—endometrium—polycystic ovary syndrome	0.000793	0.0119	CbGeAlD
Loperamide—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000791	0.0249	CcSEcCtD
Loperamide—OPRM1—endocrine gland—polycystic ovary syndrome	0.00077	0.0116	CbGeAlD
Loperamide—CALM3—female gonad—polycystic ovary syndrome	0.000765	0.0115	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000761	0.024	CcSEcCtD
Loperamide—CALM3—vagina—polycystic ovary syndrome	0.00076	0.0114	CbGeAlD
Loperamide—Discomfort—Metformin—polycystic ovary syndrome	0.000757	0.0239	CcSEcCtD
Loperamide—CALM2—uterus—polycystic ovary syndrome	0.000734	0.011	CbGeAlD
Loperamide—CALM1—uterus—polycystic ovary syndrome	0.000731	0.011	CbGeAlD
Loperamide—CALM2—pituitary gland—polycystic ovary syndrome	0.000721	0.0109	CbGeAlD
Loperamide—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00072	0.0227	CcSEcCtD
Loperamide—CALM2—adipose tissue—polycystic ovary syndrome	0.000718	0.0108	CbGeAlD
Loperamide—CALM1—pituitary gland—polycystic ovary syndrome	0.000718	0.0108	CbGeAlD
Loperamide—CALM1—adipose tissue—polycystic ovary syndrome	0.000715	0.0108	CbGeAlD
Loperamide—Skin disorder—Metformin—polycystic ovary syndrome	0.000713	0.0225	CcSEcCtD
Loperamide—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.000664	0.00998	CbGeAlD
Loperamide—CYP2C8—endometrium—polycystic ovary syndrome	0.000661	0.00994	CbGeAlD
Loperamide—Somnolence—Metformin—polycystic ovary syndrome	0.000653	0.0206	CcSEcCtD
Loperamide—Dyspepsia—Metformin—polycystic ovary syndrome	0.000646	0.0204	CcSEcCtD
Loperamide—CALM2—adrenal gland—polycystic ovary syndrome	0.000644	0.00969	CbGeAlD
Loperamide—CALM1—adrenal gland—polycystic ovary syndrome	0.000641	0.00965	CbGeAlD
Loperamide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000634	0.02	CcSEcCtD
Loperamide—Fatigue—Metformin—polycystic ovary syndrome	0.000633	0.02	CcSEcCtD
Loperamide—Constipation—Metformin—polycystic ovary syndrome	0.000628	0.0198	CcSEcCtD
Loperamide—CALM2—female gonad—polycystic ovary syndrome	0.000601	0.00904	CbGeAlD
Loperamide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.0006	0.0189	CcSEcCtD
Loperamide—CALM1—female gonad—polycystic ovary syndrome	0.000598	0.009	CbGeAlD
Loperamide—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000598	0.00899	CbGeAlD
Loperamide—CALM2—vagina—polycystic ovary syndrome	0.000597	0.00898	CbGeAlD
Loperamide—CALM1—vagina—polycystic ovary syndrome	0.000594	0.00894	CbGeAlD
Loperamide—Clotrimazole—CYP17A1—polycystic ovary syndrome	0.000592	0.212	CrCbGaD
Loperamide—Urticaria—Metformin—polycystic ovary syndrome	0.000583	0.0184	CcSEcCtD
Loperamide—Clotrimazole—CYP11A1—polycystic ovary syndrome	0.000582	0.209	CrCbGaD
Loperamide—Abdominal pain—Metformin—polycystic ovary syndrome	0.00058	0.0183	CcSEcCtD
Loperamide—CALM2—endocrine gland—polycystic ovary syndrome	0.000559	0.00841	CbGeAlD
Loperamide—CALM1—endocrine gland—polycystic ovary syndrome	0.000556	0.00837	CbGeAlD
Loperamide—Asthenia—Metformin—polycystic ovary syndrome	0.000527	0.0166	CcSEcCtD
Loperamide—Pruritus—Metformin—polycystic ovary syndrome	0.000519	0.0164	CcSEcCtD
Loperamide—Diarrhoea—Metformin—polycystic ovary syndrome	0.000502	0.0158	CcSEcCtD
Loperamide—CYP2C8—vagina—polycystic ovary syndrome	0.000495	0.00744	CbGeAlD
Loperamide—Dizziness—Metformin—polycystic ovary syndrome	0.000486	0.0153	CcSEcCtD
Loperamide—CYP2B6—adrenal gland—polycystic ovary syndrome	0.000479	0.00721	CbGeAlD
Loperamide—Vomiting—Metformin—polycystic ovary syndrome	0.000467	0.0147	CcSEcCtD
Loperamide—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000463	0.00697	CbGeAlD
Loperamide—Rash—Metformin—polycystic ovary syndrome	0.000463	0.0146	CcSEcCtD
Loperamide—Dermatitis—Metformin—polycystic ovary syndrome	0.000462	0.0146	CcSEcCtD
Loperamide—Headache—Metformin—polycystic ovary syndrome	0.00046	0.0145	CcSEcCtD
Loperamide—CYP2B6—vagina—polycystic ovary syndrome	0.000444	0.00668	CbGeAlD
Loperamide—Nausea—Metformin—polycystic ovary syndrome	0.000436	0.0138	CcSEcCtD
Loperamide—ABCB1—embryo—polycystic ovary syndrome	0.000433	0.00651	CbGeAlD
Loperamide—CYP2B6—endocrine gland—polycystic ovary syndrome	0.000415	0.00625	CbGeAlD
Loperamide—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000355	0.00534	CbGeAlD
Loperamide—CYP2D6—female gonad—polycystic ovary syndrome	0.000332	0.00499	CbGeAlD
Loperamide—Toremifene—CYP1A1—polycystic ovary syndrome	0.000328	0.118	CrCbGaD
Loperamide—ABCB1—endometrium—polycystic ovary syndrome	0.000317	0.00476	CbGeAlD
Loperamide—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000314	0.00472	CbGeAlD
Loperamide—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000309	0.00464	CbGeAlD
Loperamide—Levomethadyl Acetate—CYP19A1—polycystic ovary syndrome	0.000301	0.108	CrCbGaD
Loperamide—Clotrimazole—CYP19A1—polycystic ovary syndrome	0.000301	0.108	CrCbGaD
Loperamide—ABCB1—uterus—polycystic ovary syndrome	0.000292	0.00439	CbGeAlD
Loperamide—ABCB1—pituitary gland—polycystic ovary syndrome	0.000287	0.00431	CbGeAlD
Loperamide—ABCB1—adipose tissue—polycystic ovary syndrome	0.000285	0.00429	CbGeAlD
Loperamide—ABCB1—adrenal gland—polycystic ovary syndrome	0.000256	0.00385	CbGeAlD
Loperamide—ABCB1—female gonad—polycystic ovary syndrome	0.000239	0.00359	CbGeAlD
Loperamide—ABCB1—vagina—polycystic ovary syndrome	0.000237	0.00357	CbGeAlD
Loperamide—ABCB1—endocrine gland—polycystic ovary syndrome	0.000222	0.00334	CbGeAlD
Loperamide—Haloperidol—CYP1A1—polycystic ovary syndrome	0.000199	0.0715	CrCbGaD
Loperamide—Tamoxifen—CYP19A1—polycystic ovary syndrome	0.000178	0.0638	CrCbGaD
Loperamide—Methadone—CYP19A1—polycystic ovary syndrome	0.000177	0.0633	CrCbGaD
Loperamide—Tamoxifen—CYP1A1—polycystic ovary syndrome	0.000131	0.047	CrCbGaD
Loperamide—CALM2—Immune System—NRG1—polycystic ovary syndrome	6.37e-06	3.45e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRG1—polycystic ovary syndrome	6.37e-06	3.45e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	6.37e-06	3.44e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.34e-06	3.43e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.34e-06	3.43e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	6.29e-06	3.4e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—SLC2A4—polycystic ovary syndrome	6.28e-06	3.4e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—SLC2A4—polycystic ovary syndrome	6.28e-06	3.4e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	6.27e-06	3.39e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	6.25e-06	3.38e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	6.24e-06	3.37e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	6.24e-06	3.37e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—IL6—polycystic ovary syndrome	6.21e-06	3.36e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NCOR1—polycystic ovary syndrome	6.2e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PGR—polycystic ovary syndrome	6.18e-06	3.34e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PGR—polycystic ovary syndrome	6.18e-06	3.34e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.11e-06	3.3e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CYP19A1—polycystic ovary syndrome	6.11e-06	3.3e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IRS1—polycystic ovary syndrome	6.09e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRG1—polycystic ovary syndrome	6.08e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—IL6—polycystic ovary syndrome	6e-06	3.25e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—IL6—polycystic ovary syndrome	6e-06	3.25e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	6e-06	3.25e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NCOR1—polycystic ovary syndrome	6e-06	3.24e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NCOR1—polycystic ovary syndrome	6e-06	3.24e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	5.94e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PLAT—polycystic ovary syndrome	5.94e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GHRL—polycystic ovary syndrome	5.94e-06	3.21e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	5.93e-06	3.2e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CYP19A1—polycystic ovary syndrome	5.91e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CYP19A1—polycystic ovary syndrome	5.91e-06	3.19e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	5.9e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRG1—polycystic ovary syndrome	5.89e-06	3.18e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRG1—polycystic ovary syndrome	5.89e-06	3.18e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—POMC—polycystic ovary syndrome	5.86e-06	3.17e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	5.85e-06	3.16e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—INS—polycystic ovary syndrome	5.83e-06	3.15e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—TH—polycystic ovary syndrome	5.81e-06	3.14e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	5.77e-06	3.12e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—LEP—polycystic ovary syndrome	5.77e-06	3.12e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GHRL—polycystic ovary syndrome	5.74e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GHRL—polycystic ovary syndrome	5.74e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PLAT—polycystic ovary syndrome	5.74e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PLAT—polycystic ovary syndrome	5.74e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—VEGFA—polycystic ovary syndrome	5.69e-06	3.07e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ATF1—polycystic ovary syndrome	5.66e-06	3.06e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	5.65e-06	3.05e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CRP—polycystic ovary syndrome	5.64e-06	3.05e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IRS2—polycystic ovary syndrome	5.64e-06	3.05e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IGF1—polycystic ovary syndrome	5.64e-06	3.05e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT2—polycystic ovary syndrome	5.64e-06	3.05e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	5.6e-06	3.03e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	5.6e-06	3.03e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.52e-06	2.99e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	5.51e-06	2.98e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	5.51e-06	2.98e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—VEGFA—polycystic ovary syndrome	5.5e-06	2.97e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—VEGFA—polycystic ovary syndrome	5.5e-06	2.97e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ATF1—polycystic ovary syndrome	5.48e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ATF1—polycystic ovary syndrome	5.48e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MTHFR—polycystic ovary syndrome	5.48e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CRP—polycystic ovary syndrome	5.46e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CRP—polycystic ovary syndrome	5.46e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IRS2—polycystic ovary syndrome	5.46e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IRS2—polycystic ovary syndrome	5.46e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GNAS—polycystic ovary syndrome	5.45e-06	2.95e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.36e-06	2.9e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.34e-06	2.89e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.34e-06	2.89e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	5.33e-06	2.88e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	5.31e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MTHFR—polycystic ovary syndrome	5.3e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MTHFR—polycystic ovary syndrome	5.3e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GNAS—polycystic ovary syndrome	5.27e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GNAS—polycystic ovary syndrome	5.27e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NGFR—polycystic ovary syndrome	5.23e-06	2.83e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IRS2—polycystic ovary syndrome	5.21e-06	2.82e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—POMC—polycystic ovary syndrome	5.19e-06	2.81e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—NCOR1—polycystic ovary syndrome	5.19e-06	2.81e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PRL—polycystic ovary syndrome	5.18e-06	2.8e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	5.15e-06	2.78e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—TH—polycystic ovary syndrome	5.06e-06	2.74e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	5.06e-06	2.73e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NGFR—polycystic ovary syndrome	5.06e-06	2.73e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NGFR—polycystic ovary syndrome	5.06e-06	2.73e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IRS2—polycystic ovary syndrome	5.04e-06	2.73e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IRS2—polycystic ovary syndrome	5.04e-06	2.73e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—POMC—polycystic ovary syndrome	5.02e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—POMC—polycystic ovary syndrome	5.02e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—NCOR1—polycystic ovary syndrome	5.02e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—NCOR1—polycystic ovary syndrome	5.02e-06	2.72e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.02e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PRL—polycystic ovary syndrome	5.01e-06	2.71e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PRL—polycystic ovary syndrome	5.01e-06	2.71e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.99e-06	2.7e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—POMC—polycystic ovary syndrome	4.96e-06	2.68e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—INS—polycystic ovary syndrome	4.93e-06	2.67e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IRS1—polycystic ovary syndrome	4.93e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CYP1A1—polycystic ovary syndrome	4.92e-06	2.66e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	4.92e-06	2.66e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.92e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.91e-06	2.66e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	4.91e-06	2.65e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.83e-06	2.61e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.83e-06	2.61e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	4.77e-06	2.58e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—TH—polycystic ovary syndrome	4.77e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IRS1—polycystic ovary syndrome	4.77e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IRS1—polycystic ovary syndrome	4.77e-06	2.58e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.76e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CYP1A1—polycystic ovary syndrome	4.76e-06	2.57e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CYP1A1—polycystic ovary syndrome	4.76e-06	2.57e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.75e-06	2.57e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.75e-06	2.57e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.75e-06	2.57e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	4.74e-06	2.56e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	4.71e-06	2.55e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.64e-06	2.51e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	4.63e-06	2.5e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—MTHFR—polycystic ovary syndrome	4.59e-06	2.48e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT2—polycystic ovary syndrome	4.56e-06	2.47e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GNAS—polycystic ovary syndrome	4.56e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IRS1—polycystic ovary syndrome	4.55e-06	2.46e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.53e-06	2.45e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	4.52e-06	2.44e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—MTHFR—polycystic ovary syndrome	4.44e-06	2.4e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—MTHFR—polycystic ovary syndrome	4.44e-06	2.4e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT2—polycystic ovary syndrome	4.41e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT2—polycystic ovary syndrome	4.41e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GNAS—polycystic ovary syndrome	4.41e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.41e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IRS1—polycystic ovary syndrome	4.4e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IRS1—polycystic ovary syndrome	4.4e-06	2.38e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.37e-06	2.37e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4.36e-06	2.36e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—INS—polycystic ovary syndrome	4.36e-06	2.36e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.34e-06	2.35e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.31e-06	2.33e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	4.28e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRG1—polycystic ovary syndrome	4.26e-06	2.3e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.24e-06	2.29e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—INS—polycystic ovary syndrome	4.21e-06	2.28e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—INS—polycystic ovary syndrome	4.21e-06	2.28e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT2—polycystic ovary syndrome	4.21e-06	2.28e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.2e-06	2.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.2e-06	2.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.2e-06	2.27e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	4.13e-06	2.23e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRG1—polycystic ovary syndrome	4.12e-06	2.23e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRG1—polycystic ovary syndrome	4.12e-06	2.23e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.08e-06	2.21e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT2—polycystic ovary syndrome	4.07e-06	2.2e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT2—polycystic ovary syndrome	4.07e-06	2.2e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—SERPINE1—polycystic ovary syndrome	4e-06	2.16e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	3.99e-06	2.16e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—BCL2—polycystic ovary syndrome	3.98e-06	2.15e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	3.93e-06	2.13e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.92e-06	2.12e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	3.89e-06	2.1e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3.87e-06	2.1e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—SERPINE1—polycystic ovary syndrome	3.87e-06	2.09e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—SERPINE1—polycystic ovary syndrome	3.87e-06	2.09e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—BCL2—polycystic ovary syndrome	3.85e-06	2.08e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—BCL2—polycystic ovary syndrome	3.85e-06	2.08e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	3.82e-06	2.07e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	3.77e-06	2.04e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—INS—polycystic ovary syndrome	3.75e-06	2.03e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	3.73e-06	2.02e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PPARG—polycystic ovary syndrome	3.72e-06	2.01e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.71e-06	2e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.68e-06	1.99e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—POMC—polycystic ovary syndrome	3.67e-06	1.98e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.66e-06	1.98e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IRS2—polycystic ovary syndrome	3.65e-06	1.97e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—INS—polycystic ovary syndrome	3.65e-06	1.97e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.65e-06	1.97e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.6e-06	1.95e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—polycystic ovary syndrome	3.6e-06	1.95e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—polycystic ovary syndrome	3.6e-06	1.95e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—LEP—polycystic ovary syndrome	3.57e-06	1.93e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—POMC—polycystic ovary syndrome	3.55e-06	1.92e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—POMC—polycystic ovary syndrome	3.55e-06	1.92e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—polycystic ovary syndrome	3.54e-06	1.91e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.53e-06	1.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.53e-06	1.91e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—INS—polycystic ovary syndrome	3.53e-06	1.91e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—INS—polycystic ovary syndrome	3.53e-06	1.91e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.51e-06	1.9e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.48e-06	1.88e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—LEP—polycystic ovary syndrome	3.45e-06	1.87e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—LEP—polycystic ovary syndrome	3.45e-06	1.87e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—polycystic ovary syndrome	3.42e-06	1.85e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—polycystic ovary syndrome	3.42e-06	1.85e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.28e-06	1.77e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	3.24e-06	1.75e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	3.19e-06	1.73e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IRS1—polycystic ovary syndrome	3.19e-06	1.72e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—INS—polycystic ovary syndrome	3.17e-06	1.72e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.12e-06	1.69e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.11e-06	1.68e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.08e-06	1.67e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.08e-06	1.67e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—POMC—polycystic ovary syndrome	3.07e-06	1.66e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—INS—polycystic ovary syndrome	3.05e-06	1.65e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.03e-06	1.64e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—POMC—polycystic ovary syndrome	2.97e-06	1.61e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—POMC—polycystic ovary syndrome	2.97e-06	1.61e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—INS—polycystic ovary syndrome	2.95e-06	1.6e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—INS—polycystic ovary syndrome	2.95e-06	1.6e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—polycystic ovary syndrome	2.95e-06	1.6e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT2—polycystic ovary syndrome	2.95e-06	1.59e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—polycystic ovary syndrome	2.91e-06	1.57e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.85e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.85e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.85e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.85e-06	1.54e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.85e-06	1.54e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.82e-06	1.52e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.8e-06	1.52e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—POMC—polycystic ovary syndrome	2.78e-06	1.5e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—INS—polycystic ovary syndrome	2.77e-06	1.5e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.71e-06	1.47e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.71e-06	1.47e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.66e-06	1.44e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.62e-06	1.42e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.61e-06	1.41e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.55e-06	1.38e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.54e-06	1.38e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.42e-06	1.31e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.3e-06	1.24e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—polycystic ovary syndrome	2.26e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.18e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.18e-06	1.18e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—polycystic ovary syndrome	2.15e-06	1.16e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.14e-06	1.16e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—polycystic ovary syndrome	2.06e-06	1.12e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—polycystic ovary syndrome	1.99e-06	1.08e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—polycystic ovary syndrome	1.99e-06	1.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.93e-06	1.04e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—polycystic ovary syndrome	1.9e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.86e-06	1.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.86e-06	1.01e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—polycystic ovary syndrome	1.84e-06	9.96e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—polycystic ovary syndrome	1.84e-06	9.96e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.74e-06	9.39e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.71e-06	9.27e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.7e-06	9.21e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—polycystic ovary syndrome	1.33e-06	7.21e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—polycystic ovary syndrome	1.29e-06	6.97e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—polycystic ovary syndrome	1.29e-06	6.97e-06	CbGpPWpGaD
